ArticleCytoJournal2026
Zinc finger TRAF-type containing 1 can promote the progression and metastasis of lung adenocarcinoma.
Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Lung adenocarcinoma is a type of lung cancer that falls under the category of non-small cell carcinoma. Given its high incidence, it has attracted considerable attention. Zinc finger TRAF-type containing 1 (ZFTRAF1) was found in a two-hybrid yeast screening with muine galectin-3. However, the link between ZFTRAF1 and lung adenocarcinoma was unclear. This study aimed to explore the influencing mechanism of ZFTRAF1 on lung adenocarcinoma. Material and Methods: In this study, by silencing or overexpressing ZFTRAF1, we investigated the migration and invasion ability of A549 and HCC827 cells. In addition, the polarization effect of ZFTRAF1 on macrophages was evaluated through flow cytometry and quantitative real-time polymerase chain reaction. Finally, tumor growth and development were evaluated through histological analysis Results: ZFTRAF1 was down-regulated in normal lung cells. Silencing of ZFTRAF1 inhibited migration, invasion of A549 and HCC827 cells, and the formation of tumors. Reduction of the expression of ZFTRAF1 inhibited the epithelial-mesenchymal transition, suppressed the phosphoinositide 3-kinase-protein kinase B pathway, and enhanced the polarization of M1 macrophages. In addition, the overexpression of ZFTRAF1 showed an opposite trend compared with its silencing in A549 and HCC827 cells. Conclusion: ZFTRAF1 promotes lung cancer development. Regulating the expression level of ZFTRAF1 to interfere with the growth and migration of lung adenocarcinoma may be a new strategy for the treatment of lung adenocarcinoma. In addition, the theoretical foundation for ZFTRAF1's therapeutic use is provided in this work.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.